cm082
Small moleculeexperimental
Clinical trial activity
11 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2018 (NCT03286244)
Timeline
Indications
Mechanism of action
PDGFRB inhibitor
FLT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06730672 | Phase 2 | Dec 30, 2024 | Sun Yat-Sen University |
| NCT04434326 | Phase 1 | Aug 31, 2020 | AnewPharma, Nanjing Medical University |
| NCT04328506 | Phase 1 | Mar 31, 2020 | AnewPharma, Zhejiang University |
| NCT04222842 | Phase 1 | Dec 18, 2019 | AnewPharma, Chinese Academy of Medical Sciences |
| NCT04126668 | Phase 1 | Oct 31, 2019 | AnewPharma, Zhejiang University |
| NCT03904719 | Phase 2 | May 15, 2019 | AnewPharma |
| NCT03848611 | Phase 2 | Feb 28, 2019 | AnewPharma, Chinese Academy of Medical Sciences |
| NCT03792958 | Phase 1 | Jan 31, 2019 | AnewPharma, Huazhong University of Science and Technology |
| NCT03710863 | Phase 2 | Nov 22, 2018 | AnewPharma, Wuhan University |
| NCT03602547 | Phase 2 | Jul 31, 2018 | AnewPharma, Chinese Academy of Medical Sciences |
| NCT03286244 | Phase 1 | Feb 28, 2018 | AnewPharma, Chinese Academy of Medical Sciences |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AnewPharma | For profit | 10 | 10 | 2 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 4 | 0 | 2 | 2018 |
| Zhejiang University | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Wuhan University | Academic/Hospital | 1 | 0 | 1 | 2018 |
7 organizations
Page 1 / 1